Posters/Publications

Title
Venue
Type
Date

Significant lipid lowering by ASC41, an oral tablet, liver-targeted THRβ agonist, in a phase I randomized, double-blind, placebo controlled single- and multiple-ascending dose study

EASL International Liver Congress

poster

04/2021
Significant Improvement of NAFLD Activity Scores and Liver Fibrosis by ASC41, a Selective THR-β Agonist, in High Fat Diet Induced NASH SD Rats

EASL International Liver Congress

poster

04/2021
Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

AASLD

oral

11/2020